Total-sales growth in FY 2023 of 6.7% at CER1 included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% , based on further.
Ipsen Pharma: Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PARIS, FRANCE, 7 December 2023 - Ipsen , a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our.
Capital Markets Day 2023 - Ipsen Outlines Next Phase Of Growth & Transformation And Provides New Mid-Term Outlook menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Ipsen Pharma: Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.